This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Q1 Earnings Due on May 12: ADPT, VIR, TPTX
by Kinjel Shah
Let us take a look at three biotech companies due to release their first-quarter financial results on May 12.
Is Fear Stemming From Dividend Cuts Overblown? Stocks to Gain
by Sanghamitra Saha
Not everything is bad in terms of dividend announcement. These companies announced/raised dividends amid COVID-19 pandemic.
Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.
Biotech ETFs Poised to Benefit From Coronavirus
by Neena Mishra
Rising investor interest in coronavirus related stocks will benefit these ETFs
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
by Kinjel Shah
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
AbbVie's (ABBV) Q1 Earnings and Sales Surpass Estimates
by Zacks Equity Research
AbbVie (ABBV) beats on earnings and revenues in the first quarter of 2020. Shares up in pre-market trading.
Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat
by Zacks Equity Research
Alkermes (ALKS) beats earnings and sales estimates for the first quarter of 2020. The company withdraws its previously provided outlook for 2020 amid uncertainty related to coronavirus.
Glaxo (GSK) Q1 Earnings Beat on COVID-19-Related Stockpiling
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the first quarter. Strong demand for respiratory drugs and Shingrix along with stockpiling of certain drugs amid COVID-19 drive sales.
Healthcare ETFs to Gain on Progress in Coronavirus Vaccine
by Sweta Jaiswal, FRM
The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
Imbruvica to Offset Humira Woes in AbbVie (ABBV) Q1 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q1 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.
The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q1 top line is likely to have been impacted by biosimilar competition for Humira in international markets. However, oncology drugs may have demonstrated strong growth.
Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as for sales in first-quarter 2019. The company lowers its sales and earnings guidance to include impact of COVID-19. Shares down.
3 Stocks to Benefit From Race to Develop Coronavirus Vaccines
by Zacks Equity Research
Pharmaceutical companies and scientists are relentlessly working on developing coronavirus vaccines and the progress in trails has helped stocks to rally.
Big Drug Stock Q1 Earnings Due on Apr 28: MRK, PFE and NVS
by Kinjel Shah
Let us take a look at three big drug companies due to release their first-quarter financial results on Apr 28.
Bayer (BAYRY) Q1 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Bayer (BAYRY) beats earnings estimates for the first quarter of 2019.
Biogen (BIIB) Stock Down Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the first quarter. Stock declines.
Myovant Eyes Relugolix Approval for Advanced Prostate Cancer
by Zacks Equity Research
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix as a treatment for advanced prostate cancer.
AbbVie Gets FDA Nod for Imbruvica+Rituxan in First-Line CLL
by Zacks Equity Research
AbbVie's (ABBV) regulatory application seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan gets approval from the FDA.
4 Top Sectors of Last Week & Their Winning ETFs
by Sanghamitra Saha
These sectors topped last week and beat the broader market in a sweeping move.
Novartis To Initiate Hydroxychloroquine Study for Coronavirus
by Zacks Equity Research
Novartis (NVS) announces FDA's approval to evaluate hydroxychloroquine in hospitalized patients with COVID-19 in a late-stage study. The company is evaluating several of its drugs to treat COVID-19.
The Zacks Analyst Blog Highlights: Netflix, Costco, GlaxoSmithKline, Johnson & Johnson and Cigna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Costco, GlaxoSmithKline, Johnson & Johnson and Cigna
5 Best Leveraged ETF Areas of Last Week
by Sanghamitra Saha
If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.